Aster DM Quality

Q1 FY26Healthcare Services

Aster DM Quality Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹765

Market cap₹66.4K Cr

P/E183.9

Updated26 Aug 2026

Read5 min read

The short version

Aster DM Healthcare expects 7-8% growth in both volumes and ARPOB (Average Revenue Per Occupied Bed) for FY26. Revenue growth is expected to return to double-digit figures within a couple of quarters, following a subdued performance in recent quarters due to leadership changes and specific decisions (Page 21).

From Aster DM Quality's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Aster DM Healthcare expects 7-8% growth in both volumes and ARPOB (Average Revenue Per Occupied Bed) for FY26.
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in Q4 FY25.
The company anticipates returning to double-digit growth in volumes and revenue within a couple of quarters.
Over a longer 3-4 year horizon, a 7-8% sustainable ARPOB growth is targeted, supported by specialty mix changes and oncology growth.
New hospital expansions and bed additions (2,600 beds by Aster and 1,200 beds by QCIL in pipeline) are expected to drive future revenue growth.
OPD (Outpatient Department) business is growing fast (12% volume growth) and expected to contribute favorably to ARPOB and overall revenue growth.
The company aims to continue ramping up new units rapidly, with some showing top-line growth of 25% quarter-over-quarter.

Profitability & Margins

Revenue growth is expected to return to double-digit figures within a couple of quarters, following a subdued performance in recent quarters due to leadership changes and specific decisions (Page 21).
Mid-term growth (3-4 years horizon) is projected at mid-teen levels, split roughly equally between volume growth (7-8%) and ARPOB (Average Revenue Per Occupied Bed) growth (7-8%) (Page 12).
ARPOB growth drivers include price increases, case mix improvements (notably oncology), and efficient ALOS (Average Length of Stay) management, supporting sustainable margin expansion (Pages 15-17).
Brownfield expansions are EBITDA and margin accretive with minimal payback period impact; greenfield payback period estimated around 9-10 years, with capex around INR 1-1.1 crore per bed (Pages 12-13).
Andhra & Telangana cluster EBITDA margins dip expected to normalize to 12-13% in coming quarters after initial clinical talent onboarding costs (Page 23).
Optimizations and synergies post-merger (e.g., insourcing, revenue cycle management) are expected to drive further profitability improvements (Page 17).

See what Aster DM Quality said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Aster is adding approximately 2,600 beds over the next 3-4 years, requiring about INR 2,500 crores in project CAPEX, with INR 400-500 crores already spent as of June 30; the remaining INR 2,000 crores to be spent over the next years.
For the current FY26, cumulative CAPEX including projects is estimated between INR 800 to 900 crores.
New projects like the Yeswanthpur hospital in Bangalore are greenfield developments funded through a mix of internal accruals and external funds, with CAPEX spread over roughly 20 months.
Brownfield expansions are EBITDA accretive with minimal margin dilution and faster payback compared to greenfield expansions, which have a payback of about 9-10 years.
QCIL also has a pipeline of about 1,200 beds that are being added or expanded.
Overall, the group targets around 14,000 beds over 2-3 years combining Aster and QCIL expansions.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹654 Cr

Rev 2Mar 2

4₹1.3L Cr

Rev 2Mar 3

5₹94.4K Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no specific mention of any immediate new fundraising through debt or equity in the transcript.
Funding for new projects, such as the Yeswanthpur hospital in Bangalore, will be through a mix of internal and external funds.
The company has strong cash flows from operations, converting more than 80-85%, and expects internal accruals to cover most funding needs.
At the combined level of Aster and QCIL, net debt is near zero as of FY24, indicating a strong balance sheet.
No material increase in debt is expected; any debt on QCIL is significantly lower than their EBITDA.
Capex for expansions (like the 2,600 new beds) will be around INR 2,500 crores over 3-4 years, with INR 400-500 crores already spent.
Therefore, future funding will largely rely on internal resources with selective external funding as needed, not highlighting any major new equity or debt raise.

See what Aster DM Quality said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

For Aster DM Healthcare, the project capex for adding approximately 2,600 beds is about INR 2,500 crores.
Out of this, INR 400 to 500 crores have already been incurred as of 30th June.
The remaining INR 2,000 crores is expected to be spent over the next 3-4 years.
For QCIL, cumulative CAPEX outlay including upcoming projects is expected to be about INR 800 to 900 crores this year.
Yearly operational CAPEX is roughly 5% of the topline, consistent with prior years.
Brownfield expansions, such as adding 100 beds in Kerala clusters, have a positive impact on EBITDA and margins with immediate accretion.
Greenfield projects like the new Bangalore hospital have a CAPEX timeline of around 20 months to 1.5-2 years.

Aster DM Quality — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹154 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Aster DM Quality's management said in earlier quarters

Others in Healthcare Services this season

Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene Intl. (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Rainbow Child. (Q1 FY26)
Around 50% of the total planned bed additions will be on an asset-light model. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1 FY26 earnings…

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aster DM Quality Q1 FY26 results?

What is Aster DM Quality share price analysis?

Aster DM Quality currently shows a neutral. The stock trades at a P/E of 183.9 with a market cap of ₹66,382 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aster DM Quality planning capital expenditure?

Aster is adding approximately 2,600 beds over the next 3-4 years, requiring about INR 2,500 crores in project CAPEX, with INR 400-500 crores already spent as of June 30; the remaining INR 2,000 crores to be spent over the next years.

Keep Aster DM Quality on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.